Redx Pharma plc Notice of Interim Results (5097Z)
May 24 2021 - 2:00AM
UK Regulatory
TIDMREDX
RNS Number : 5097Z
Redx Pharma plc
24 May 2021
REDX PHARMA PLC
("Redx" or the "Company")
Notice of Interim Results
Alderley Park, 24 May 2021 Redx Pharma (AIM: REDX), the drug
discovery and development company focused on cancer and fibrosis,
will be releasing its interim results for the six months ended 31
March 2021 on 7 June 2021.
A live webcast will be held at 12:00pm BST on 7 June 2021 for
analysts. To join the webcast, please register in advance by
sending an e-mail to redxpharma@fticonsulting.com
A recording of the webcast will be made available on Redx
Pharma's website following the webcast.
For further information, please contact:
Redx Pharma Plc T: +44 1625 469 918
Iain Ross, Chairman
Lisa Anson, Chief Executive
Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 203 368 3550
Matt Davis/Adam Dawes
WG Partners LLP (Joint Broker) T: +44 20 3705 9330
Claes Spång/Nigel Birks/David Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 20 7886 2500
Rupert Dearden/Freddy Crossley/Emma Earl
FTI Consulting T: +44 20 3727 1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and
development of novel targeted medicines for the treatment of cancer
and fibrotic disease, aiming to progress them to clinical proof of
concept. Redx's lead oncology asset, RXC004, is currently in a
Phase 1 study in patients with advanced malignancies with top line
monotherapy data expected in mid-2021 and the Company's selective
ROCK2 inhibitor, RXC007, is expected to enter a Phase 1 clinical
study in H1 2021.
The Company's core capability of converting medicinal chemistry
insights into differentiated and commercially attractive small
molecule drug candidates against clinically validated targets has
been recognised by others. Over the last three years the company
has completed four major preclinical stage deals with AstraZeneca,
Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORAJMPTMTTTBTB
(END) Dow Jones Newswires
May 24, 2021 02:00 ET (06:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Jul 2023 to Jul 2024